Strickler, J., Ng, K., Cercek, A., Fountzilas, C., Sanchez, F., Hubbard, J., … Bekaii-Saab, T. (2020). 523TiP MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer. In Annals of Oncology (Vol. 31, pp. S460–S461). Elsevier BV. https://doi.org/10.1016/j.annonc.2020.08.2066

Strickler, J., K. Ng, A. Cercek, C. Fountzilas, F. Sanchez, J. Hubbard, C. Wu, M. Stecher, L. N. Walker, and T. Bekaii-Saab. “523TiP MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer.” In Annals of Oncology, 31:S460–61. Elsevier BV, 2020. https://doi.org/10.1016/j.annonc.2020.08.2066.

Strickler J, Ng K, Cercek A, Fountzilas C, Sanchez F, Hubbard J, et al. 523TiP MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer. In: Annals of Oncology. Elsevier BV; 2020. p. S460–1.

Strickler, J., et al. “523TiP MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer.” Annals of Oncology, vol. 31, Elsevier BV, 2020, pp. S460–61. Crossref, doi:10.1016/j.annonc.2020.08.2066.

Strickler J, Ng K, Cercek A, Fountzilas C, Sanchez F, Hubbard J, Wu C, Stecher M, Walker LN, Bekaii-Saab T. 523TiP MOUNTAINEER: Open-label, phase II study of tucatinib combined with trastuzumab for HER2-positive metastatic colorectal cancer. Annals of Oncology. Elsevier BV; 2020. p. S460–S461.